Drugs / AR11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01986062 | Dec 2013 → May 2014 | attention deficit-hyperactivity disorder | Arbor Pharmaceuticals, Inc. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01986062 ↗ |
| Route | Oral | “AR11, administered orally, BID, for one week” NCT01986062 ↗ |